阅读说明：本技术 Hvad昼夜节律***(phi+) (HVAD circadian rhythm tracker (PHI +) ) 是由 N·沃斯克博尼科夫 P·E·格雷夫德佩拉尔塔 V·拉莫斯 于 2017-07-13 设计创作，主要内容包括：一种检测具有植入式血泵的患者的昼夜节律的中断的方法,该方法包括基于由植入式血泵消耗的用于维持植入式血泵的推进器的恒定旋转速度的功率来计算移动平均值收敛发散(MACD)以及当计算的MACD未越过MACD零线达预先确定的MACD零线越过时间阈值时生成警报。(A method of detecting an interruption of a circadian rhythm of a patient having an implantable blood pump, the method comprising calculating a moving average convergent-divergent (MACD) based on power consumed by the implantable blood pump for maintaining a constant rotational speed of a propeller of the implantable blood pump and generating an alarm when the calculated MACD does not cross the MACD zero line by a predetermined MACD zero line crossing time threshold.)

1. A system for detecting disruption of circadian rhythm of a patient having an implantable blood pump, the system comprising:

a controller having a processor, the controller in communication with the implantable blood pump and a power supply configured to provide power to the implantable blood pump, the controller configured to:

calculating a Moving Average Convergent Divergent (MACD) based on power consumed by the implantable blood pump to maintain a constant rotational speed of a propeller of the implantable blood pump; and is

An alarm is generated when the calculated MACD does not cross the MACD zero line by a predetermined MACD zero line crossing time threshold.

2. The system of claim 1, wherein the MACD zero line crossing time threshold is 24 hours.

3. The system of any one of claims 1 or 2, wherein calculating the MACD comprises calculating a slow-moving average (SMA), and wherein the SMA is a one-second average measurement of power consumed by the implantable blood pump measured at predetermined intervals for a first predetermined period of time.

4. The system of claim 3, wherein the predetermined interval is 15 minutes.

5. The system of claim 4, wherein the first predetermined period of time is 48 hours.

6. The system of claim 3, wherein calculating the MACD comprises calculating a Fast Moving Average (FMA), and wherein the FMA is a one second average measurement of power consumed by the implantable blood pump measured at the predetermined intervals for a second predetermined time period that is less than the first time period.

7. The system of claim 6, wherein the second predetermined period of time is four hours.

8. The system of any one of claims 1-7, wherein generating an alert comprises at least one from the group consisting of sounding an alarm on a controller of the implantable blood pump and displaying a time and date of the alert on a display of the controller of the implantable blood pump.

9. The system of any one of claims 1-8, wherein the controller is further configured to clear the alarm when the calculated MACD crosses the MACD zero line within the predetermined MACD zero line crossing time threshold.

10. The system of any one of claims 1-9, wherein the patient has a circadian cycle, and wherein generating the alert indicates a loss of the patient's circadian cycle.

11. The system of claim 10, wherein the controller is further configured to correlate the loss of the patient's circadian cycle with a thrombotic condition.

12. The system of claim 10, wherein the controller is further configured to correlate the loss of the patient's circadian cycle with a tachycardia condition.

Technical Field

The present invention relates to a method and system for detecting an interruption of a circadian rhythm of a patient having an implantable blood pump.

Background

A ventricular assist device or VAD is a life-saving mechanical circulatory support device or MCSD configured to assist the heart in pumping blood throughout the body. The VAD may include a centrifugal pump, an axial flow pump, or other type of electromagnetic pump configured to pump blood from the heart to the blood vessels to circulate around the body. One such centrifugal pump is the HVAD sold by HeartWare corporation and is shown and described in U.S. patent No. 7,997,854, which is incorporated herein by reference in its entirety. One such axial flow pump is the MVAD sold by HeartWare corporation and shown and described in U.S. patent No. 8,419,609, which is incorporated herein by reference in its entirety.

Since patients requiring such devices often have different heart pathologies that require implantation of a VAD in the patient, detecting patient adverse events associated with implantation of a VAD is challenging. One solution designed is to implant a sensor in or on the VAD to detect an operating parameter of the blood pump. However, implanting a sensor in or on a VAD requires sensor calibration and may be affected by potential failure due to corrosion or other events and increases the power necessary to operate the VAD.

Disclosure of Invention

A system of one or more computers may be configured to perform particular operations or actions by virtue of installing software, firmware, hardware, or a combination thereof on the system that, in operation, causes the system to perform the actions. One or more computer programs may be configured to perform particular operations or actions by virtue of comprising instructions that, when executed by data processing apparatus, cause the apparatus to perform the actions. One general aspect includes a method for detecting an interruption of a circadian rhythm of a patient having an implantable blood pump, comprising: calculating a Moving Average Convergence Divergence (MACD) based on power consumed by the implantable blood pump to maintain a constant rotational speed of a propeller of the implantable blood pump; and generating an alarm when the calculated MACD does not cross the MACD zero line by a predetermined MACD zero line crossing time threshold. Other embodiments of this aspect include corresponding computer systems, apparatus, and computer programs recorded on one or more computer storage devices, each configured to perform the actions of the methods.

Drawings

A more complete understanding of the present invention, and the attendant advantages and features thereof, will be more readily understood by reference to the following detailed description when considered in conjunction with the accompanying drawings wherein:

fig. 1 is an exemplary display of a log file of an implantable blood pump operating within normal parameters;

FIG. 2 is an exemplary flow chart illustrating a method of determining an interruption of a circadian rhythm of a patient having an operating blood pump according to the application;

fig. 3 is an exemplary display of a log file for an implantable blood pump operating within normal parameters;

FIG. 4 is the log file of FIG. 3, wherein the MACD calculations are shown and operating within normal parameters for a two-day period;

fig. 5 is an exemplary display of a log file for an implanted blood pump operating abnormally;

FIG. 6 is the log file of FIG. 5, wherein the displayed MACD calculations indicate a loss of circadian rhythm;

fig. 7 is an exemplary display of a log file for an implanted blood pump operating abnormally;

FIG. 8 is the log file of FIG. 7, wherein the MACD calculations displayed indicate the presence of a thrombus;

fig. 9 is an exemplary display of a log file for an implanted blood pump operating abnormally; and is

Figure 10 is the log file of figure 9 in which the displayed MACD calculations indicate the presence of ventricular tachycardia.

Implementations may include one or more of the following features. In this method, the MACD zero line crossing time threshold is 24 hours. In the method, calculating the MACD comprises calculating a slow-moving average (SMA), and wherein the SMA is a one-second average measurement of the power consumed by the implantable blood pump measured at predetermined intervals for a first predetermined period of time. In this method, the predetermined interval is 15 minutes. In this method, the first predetermined period of time is 48 hours. In the method, calculating the MACD includes calculating a Fast Moving Average (FMA), and wherein the FMA is a one second average measurement of power consumed by the implantable blood pump measured at predetermined intervals for a second predetermined time period that is less than the first time period. In this method, the second predetermined period of time is four hours. In the method, the patient has a circadian cycle, and wherein generating the alert indicates a loss of the circadian cycle of the patient. In the method, the method further comprises correlating the loss of the patient's circadian cycle with at least one from the group comprising thrombosis and tachycardia. In the method, generating the alarm comprises at least one from the group consisting of sounding an alarm (alarm) on a controller of the implantable blood pump and displaying a time and date of the alarm in a log file of the controller of the implantable blood pump. Implementations of the described technology may include hardware, methods or processes, or computer software on a computer-accessible medium.

One general aspect includes a system for detecting disruption of circadian rhythm of a patient having an implantable blood pump, comprising: a controller having a processor, the controller in communication with the implantable blood pump and a power supply configured to provide power to the implantable blood pump, the controller configured to calculate a Moving Average Convergent Divergent (MACD) based on power consumed by the implantable blood pump to maintain a constant rotational speed of a propeller of the implantable blood pump; and generating an alarm when the calculated MACD does not cross the MACD zero line by the predetermined MACD zero line crossing time threshold. Other embodiments of this aspect include corresponding computer systems, apparatus, and computer programs recorded on one or more computer storage devices, each configured to perform the actions of the methods.